SG11202102160VA - Markers useful in enrichment strategies for the treatment of osteoarthritis - Google Patents

Markers useful in enrichment strategies for the treatment of osteoarthritis

Info

Publication number
SG11202102160VA
SG11202102160VA SG11202102160VA SG11202102160VA SG11202102160VA SG 11202102160V A SG11202102160V A SG 11202102160VA SG 11202102160V A SG11202102160V A SG 11202102160VA SG 11202102160V A SG11202102160V A SG 11202102160VA SG 11202102160V A SG11202102160V A SG 11202102160VA
Authority
SG
Singapore
Prior art keywords
osteoarthritis
treatment
markers useful
enrichment strategies
enrichment
Prior art date
Application number
SG11202102160VA
Other languages
English (en)
Inventor
Christoph Ladel
Hans Guehring
Anne-Christine Bay-Jensen
Morten Karsdal
Per Qvist
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SG11202102160VA publication Critical patent/SG11202102160VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
SG11202102160VA 2018-09-10 2019-09-09 Markers useful in enrichment strategies for the treatment of osteoarthritis SG11202102160VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18193351 2018-09-10
PCT/EP2019/074003 WO2020053155A1 (en) 2018-09-10 2019-09-09 Markers useful in enrichment strategies for the treatment of osteoarthritis

Publications (1)

Publication Number Publication Date
SG11202102160VA true SG11202102160VA (en) 2021-04-29

Family

ID=63685561

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202102160VA SG11202102160VA (en) 2018-09-10 2019-09-09 Markers useful in enrichment strategies for the treatment of osteoarthritis

Country Status (12)

Country Link
US (1) US20220047674A1 (zh)
EP (1) EP3850113B1 (zh)
JP (1) JP2022511305A (zh)
KR (1) KR20210057764A (zh)
CN (1) CN113286896A (zh)
AU (1) AU2019337786A1 (zh)
BR (1) BR112021004356A2 (zh)
CA (1) CA3111671A1 (zh)
IL (1) IL281333A (zh)
MX (1) MX2021002803A (zh)
SG (1) SG11202102160VA (zh)
WO (1) WO2020053155A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113425855B (zh) * 2021-06-28 2023-11-07 深圳瑞吉生物科技有限公司 一种mRNA剂型的骨关节炎药物制剂及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837841A (en) 1996-10-11 1998-11-17 Incyte Pharmaceuticals, Inc. Human Reg protein
AU2003279835B2 (en) 2002-10-07 2009-09-10 Zymogenetics, Inc. Methods of administering FGF18
JP5815206B2 (ja) 2006-08-25 2015-11-17 アレス トレーディング ソシエテ アノニム Ｆｇｆ−１８を用いた軟骨障害の治療
JP2009257842A (ja) * 2008-04-14 2009-11-05 Ttc:Kk 変形性関節症の検査方法及び診断用キット
JP5762282B2 (ja) * 2008-05-02 2015-08-12 インタールーキン ジェネティクス， インコーポレイテッド 変形性関節症に関連する状態に対する遺伝的素因の検出
US20090299769A1 (en) * 2008-05-29 2009-12-03 Nordic Bioscience Imaging A/S Prognostic osteoarthritis biomarkers
CN104736723B (zh) * 2012-08-06 2017-10-31 默克专利有限公司 用于预测对fgf‑18化合物的响应性的遗传标记
US10899757B2 (en) * 2015-11-06 2021-01-26 Samumed, Llc 2-(1H-indazol-3-yl)-3H-imidazo[4,5-C]pyridines and their anti-inflammatory uses thereof
US9983214B2 (en) * 2016-04-15 2018-05-29 Esm Technologies, Llc Method for evaluating articular joint therapeutics
HUE058786T2 (hu) * 2017-09-29 2022-09-28 Merck Patent Gmbh FGF-18 vegyületre vonatkozó válaszkészség elõrejelzésére szolgáló metabolikus biomarkerek

Also Published As

Publication number Publication date
IL281333A (en) 2021-04-29
WO2020053155A1 (en) 2020-03-19
BR112021004356A2 (pt) 2021-08-03
EP3850113A1 (en) 2021-07-21
MX2021002803A (es) 2021-07-16
CA3111671A1 (en) 2020-03-19
KR20210057764A (ko) 2021-05-21
EP3850113B1 (en) 2024-04-03
US20220047674A1 (en) 2022-02-17
CN113286896A (zh) 2021-08-20
JP2022511305A (ja) 2022-01-31
AU2019337786A1 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
IL283948A (en) Methods for treating depression
AP2016009497A0 (en) Process for the treatment of high sulphate waters
SI3377064T1 (sl) Orvepitant za zdravljenje kroničnega kašlja
IL281792A (en) Treatment methods
IL281839A (en) Treatment methods
PT3393983T (pt) Métodos para aumentar a desidratabilidade de lamas com tratamento enzimático
ZA202001536B (en) Method for the treatment of wastewaters
SG11202102160VA (en) Markers useful in enrichment strategies for the treatment of osteoarthritis
ZA201901505B (en) Phenylalanine-free protein for the treatment of pku
GB201808575D0 (en) Methods for the treatment of psoriatic arthrits
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
EP3294339A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF ARTHRITIS
SI3548006T1 (sl) Sestava za uporabo pri zdravljenju črevesnih sprememb
IL254450B (en) A preparation for use in the treatment of displaced vertebrae
FR3020005B1 (fr) Fut en bois pour le vieillissement d'un spiritueux et procede de vieillissement d'un spiritueux
IL267059A (en) A preparation for the treatment of osteoarthritis
SG11202100269VA (en) Compounds for use in the treatment of fascioliasis
ZA201906542B (en) Process for the treatment of wastewater
HUP1800397A2 (en) Process for the preparation of lumateperone and salts thereof
GB201820914D0 (en) water treatment composition
GB201620028D0 (en) 24/7 Banker
GB201522945D0 (en) The equipment for electroplating wastewater treatment
GB201501446D0 (en) Improved process for the treatment of high sulphate waters
EP3204043C0 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CONTAINING 5-IODO-2-PYRIMIDINONE-2'-DEOXYRIBOSE (IPDR)